We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Thermo Fisher Scientific (TMO) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Thermo Fisher Scientific (TMO - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of TMO and the rest of the Medical group's stocks.
Thermo Fisher Scientific is a member of the Medical sector. This group includes 841 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. TMO is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for TMO's full-year earnings has moved 0.63% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that TMO has returned about 27.06% since the start of the calendar year. In comparison, Medical companies have returned an average of 2.55%. This shows that Thermo Fisher Scientific is outperforming its peers so far this year.
Breaking things down more, TMO is a member of the Medical - Instruments industry, which includes 93 individual companies and currently sits at #74 in the Zacks Industry Rank. This group has gained an average of 15.32% so far this year, so TMO is performing better in this area.
Investors with an interest in Medical stocks should continue to track TMO. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Thermo Fisher Scientific (TMO) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Thermo Fisher Scientific (TMO - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of TMO and the rest of the Medical group's stocks.
Thermo Fisher Scientific is a member of the Medical sector. This group includes 841 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. TMO is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for TMO's full-year earnings has moved 0.63% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that TMO has returned about 27.06% since the start of the calendar year. In comparison, Medical companies have returned an average of 2.55%. This shows that Thermo Fisher Scientific is outperforming its peers so far this year.
Breaking things down more, TMO is a member of the Medical - Instruments industry, which includes 93 individual companies and currently sits at #74 in the Zacks Industry Rank. This group has gained an average of 15.32% so far this year, so TMO is performing better in this area.
Investors with an interest in Medical stocks should continue to track TMO. The stock will be looking to continue its solid performance.